



UPDATED

GLP-1 for WEIGHT LOSS COMMUNICATION

Last September, VEHI communicated to its member groups and subscribers that it was suspending coverage of GLP-1 medications for weight loss, while maintaining coverage of these prescriptions for patients with diabetes and those diagnosed with MACE – a major adverse cardiac event.

Unfortunately, at the time of the communication, we did not have full details on the prior-approval criteria for Wegovy, a GLP-1 medication specific to treat MACE. We researched this matter further, and with assistance from Blue Cross of Vermont, updated our earlier communication. You can access the new version [here](#). The revised section on MACE is found on page 2.

Once again, our apologies for the lack of specificity in the earlier communication.

For more information about this change, please see our [full updated memo](#).

This notification has been sent to School Business Officials, Human Resources Professionals, Local Union Officials and other Health Plan Employers.

To avoid confusion and to ensure consistency in the delivery of information, when distributing VEHI information do not modify any VEHI communications or attachments.

Please note: For your convenience, all VEHI Communications (sent via Campaign Monitor) can now be found in our archive at vehi.org/campaign-monitors.

You're receiving this notification because your school and/or SU are a member of our program.

[Edit your subscription](#) | [Unsubscribe](#)

52 Pike Drive
Berlin, VT 05602
(802) 223-5040